Gilead Sciences (NASDAQ:GILD) Updates FY 2020 Pre-Market Earnings Guidance

Share on StockTwits

Gilead Sciences (NASDAQ:GILD) issued an update on its FY 2020
Pre-Market earnings guidance on Monday morning. The company provided earnings per share guidance of -0.08-0.02 for the period. Gilead Sciences also updated its FY20 guidance to $6.98-7.08 EPS.

NASDAQ:GILD opened at $61.54 on Thursday. The firm’s 50-day moving average is $59.86 and its 200-day moving average is $64.79. Gilead Sciences has a 52-week low of $56.56 and a 52-week high of $85.97. The company has a debt-to-equity ratio of 1.65, a quick ratio of 3.15 and a current ratio of 3.25. The company has a market cap of $77.14 billion, a price-to-earnings ratio of 63.44, a PEG ratio of 0.70 and a beta of 0.52.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.90 by $0.21. Gilead Sciences had a net margin of 5.48% and a return on equity of 37.77%. The company had revenue of $6.58 billion for the quarter, compared to the consensus estimate of $6.20 billion. Equities analysts predict that Gilead Sciences will post 6.63 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th were given a dividend of $0.68 per share. The ex-dividend date was Monday, December 14th. This represents a $2.72 annualized dividend and a dividend yield of 4.42%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.30%.

GILD has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Gilead Sciences from a sell rating to a hold rating and set a $65.00 target price on the stock in a research report on Monday, October 19th. Truist Financial reduced their price target on shares of Gilead Sciences from $67.00 to $625.00 in a research report on Friday, December 18th. UBS Group started coverage on shares of Gilead Sciences in a research report on Wednesday, October 28th. They issued a neutral rating and a $61.00 price target on the stock. Robert W. Baird boosted their price target on shares of Gilead Sciences from $63.00 to $67.00 and gave the company a neutral rating in a research report on Wednesday, December 16th. Finally, Jefferies Financial Group started coverage on shares of Gilead Sciences in a research report on Wednesday, September 30th. They issued a buy rating and a $78.00 price target on the stock. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $92.87.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: What does an equal weight rating mean?

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with's FREE daily email newsletter.